Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
20 NC counties are under alert, including Johnston County.
Closings
1 closing/delay reported.
Just In
Helene recovery: Want to help residents impacted by Tropical Storm Helene? Here's how you can
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TCR2 Therapeutics
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
February 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Announces Pipeline Priorities for 2023
January 05, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
November 23, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 07, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
September 28, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 27, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.